Todd Krueger is the Chief Executive Officer, President and a Director of our Company. He is primarily responsible for the overall management, corporate development and strategic planning of our Company and has been with the company since 2015. Mr. Krueger graduated from Northwestern University, United States, with a Bachelor of Economics degree with Highest Distinction, and earned his Master of Business Administration degree from the Kellogg School of Management, Northwestern University, United States.
Prior to joining us, Mr. Krueger had over 20 years of experience in healthcare strategy, business development, operations and finance. He started his career as a consultant for Bain and Company, a management consulting firm, from 1990 to 1993, responsible for providing strategic analysis and solution implementation to Fortune 500 clients. In 1999, Mr. Krueger co-founded Fluidigm Corporation, which is principally engaged in the design, manufacture and sale of biological research equipment and is currently listed on NASDAQ (stock symbol FLDM), where he served as its chief financial officer and the vice-president of business development from 1999 to 2002, responsible for strategy development, finance, business development, and operations. From 2006 to 2013 he held various senior business development and strategy roles at Applied Biosystems Inc. and later Life Technologies Corporation (which was formed as a result of the merger between Applied Biosystems Inc. and Invitrogen Corporation in 2008)), where his last role was head of business development for molecular medicine. From 2013 to 2014, he was Chief Financial Officer of Claritas Genomics, Inc., a genetic diagnostics laboratory based in the United States, and from 2014 to 2015, he was the director of strategy and operations for the Broad Institute, a biomedical and genomic research center based in the United States. He was responsible for overseeing the commercialization of the genetics platform.
Mr. Krueger also currently serves as a director of General Automation Laboratory Technologies, Inc. (GALT), a microbiome tools company based in the United States.
Lauren Ambrogiois the Chief Operating Officer of our Company. Since going the company in 2016, she is primarily responsible for supervising and overseeing the overall business operations of our Company, overseeing our Intellectual Properties matters, and providing scientific strategy and leadership. She graduated from the University of Rochester, United States, with a Bachelor of Science degree majoring in Molecular Genetics.
From 2006 to 2008, Ms. Ambrogio was a research technician at Dana Farber Cancer Institute, a cancer treatment research center based in United States, where she was responsible for executing front-line research experiments on the molecular basis of various cancers as well as performing pre-clinical in vitroassays testing putative targeted drug therapies. From 2008 to 2014, Ms. Ambrogio held multiple roles at the Broad Institute, a biomedical and genomic research center based in the United States, with her last position as project manager, cancer genome projects, where she was responsible for overseeing cancer genomic research studies. From 2013 to 2014, Ms. Ambrogio was the project and product portfolio manager of Claritas Genomics, Inc., a genetics diagnostic laboratory based in the United States, where she was responsible for its project management and product development efforts. From 2014 to 2016, she was the chief operating officer of Q-State Biosciences, Inc., a drug discovery company based in the United States, where she was responsible for leadership and oversight of its operations.
Ms. Ambrogio is an author on 23 peer-reviewed scientific papers and has been involved in multiple scientific projects such as the National Institutes of Health funded 1000 Genomes Project and The Cancer Genome Atlas project.
Judi Ng Cashin is the Chief Medical Officer of our Company. She brings a wealth of experience to the team in both early and late stage drug development with major pharmaceutical companies where she managed clinical research, interacted with the FDA, and developed clinical and portfolio strategies. Most recently, Judi served as Chief Scientific Officer at Syneos Health, a pharmaceutical services provider created by the merger of INC Research and inVentiv Health, where she led the integration of the therapeutic, medical, and scientific operations within product development and Phase 1-4 trial delivery. Prior to Syneos, Judi served as the Vice President of Medical Strategy and then of Advisory Services for IQVIA, formerly Quintiles, a management consultancy focused on biopharma and the healthcare industry. Her experience also includes nine years with GlaxoSmithKline (GSK) in senior medical leadership roles including, Vice President of Medical Excellence and Quality, Vice President and Global Head, Infectious Diseases Medicines Development Center, as well as Vice President of Stiefel Laboratories, GSK’s dermatology franchise focusing on acne treatments and anti-infectives.
Ramesh Ratanis the Chief Financial Officer and Senior Vice President of Manufacturing of our Company. Since joining the company in 2015, he is primarily responsible for supervising and overseeing the overall financial management and product manufacturer for the Group. He graduated from Madhav Institute of Technology and Science, India, with a Bachelor of Electrical Engineering degree.
Mr. Ratan has over 40 years of experience in finance and administration. From 1976 to 1986, he was a manager of industrial engineering, director of marketing finance, director of manufacturing accounting and director of financial planning and analysis of Bristol-Myers Squibb, a pharmaceutical company based in United States. From 1986 to 1994, he was the senior vice president of administration, chief financial officer and corporate secretary of Repligen Corporation, an American manufacturer of materials used in producing biological drugs, responsible for overseeing its financial management and reporting functions. From 1995 to 1997, he was the executive vice president of business development, chief financial officer and corporate secretary of American Superconductor Corporation, which principally engages in manufacturing of power systems and superconducting wire and is currently listed on the NASDAQ (stock symbol AMSC). He was responsible for overseeing its business development and financial administration functions. From 1997 to 2001, he was the executive vice president of corporate development and the chief financial officer of Equinox Solutions, an information technology company based in United States, responsible for overseeing its corporate development and financial management. From 2001 to 2003, he was the senior vice president of finance and administration and the chief financial officer of Enanta Pharmaceuticals, Inc., a biotech company which develops drugs for hepatitis C virus, where he was responsible for overseeing its financial functions and management. From 2004 to 2007, he was chief financial officer of Xcellerex, Inc., a bio pharmaceutical manufacturer based in United States, responsible for overseeing its financial management and reporting functions. From 2008 to 2017, he was the chief financial officer and corporate secretary of ABOVE Solutions, Inc., an information technology company, responsible for overseeing its financial management and reporting functions.
Spiros Jamas is the Senior Vice President of Therapeutic Development of our Company. He is primarily responsible for therapeutics strategy and development, clinical development and regulatory affairs. He co-founded AOBiome LLC in May 2013. He graduated from the University of Manchester, United Kingdom, with a Bachelor of Science majoring in Chemical Engineering, and from Massachusetts Institute of Technology, United States with a Master of Science majoring in food science and technology and a Doctor of Science majoring in Biotechnology.
Dr. Jamas has over 24 years of experience in the biopharmaceutical industry. From 1988 to 1999, he served as chief executive officer of Alpha-Beta Technology, Inc., a biotech company developing a first-in-class biologic immunomodulator, where he was responsible for its strategic development, clinical development and regulatory affairs. From 2001 to 2004, he served as chief executive officer of Enanta Pharmaceuticals, Inc., a biotech company which develops drugs for hepatitis C virus, where he was responsible for its strategic development and general management. From 2004 to 2009, he was a biotechnology/pharma analyst for the global fundamental strategies team of State Street Global Advisors, an asset management company, where he was responsible for stock analyses as well as clinical/regulatory due diligence. In 2010, he co-founded Tempero Pharmaceuticals, Inc., a biotech company which is now a part of the GlaxoSmithKline group, to develop drugs for inflammatory and autoimmune diseases.
Jim Hoffmanis a Director of our Company. Since joining the company in 2015, he is primarily responsible for the overall management, marketing and technology strategy of our Company.
Prior to joining us, Mr. Hoffman had over 40 years of experience in the technology, marketing and entertainment businesses. Throughout his career, he founded a number of business, including:
• Computers Etc., which was a chain of computer retail stores, where he served as executive vice president from 1977 to 1982 mainly responsible for its sales and marketing functions and international expansion management;
• Seequa Computer Corporation, which was a manufacturer of portable computers, where he served as executive vice president from 1982 to 1985 mainly responsible for its sales and marketing functions and R&D matters;
• Journal Graphics Inc., which was a broadcast transcript company, where he served as the president and chief executive officer from 1992 to 1994 mainly responsible for its executive management and strategy;
• Bigfoot Interactive, which was a provider of electronic marketing solutions, where he served as chief executive officer from 1995 to 2000 mainly responsible for its executive management and strategy; and
• Section 101, which is an interactive marketing agency, where he served as chief technical officer from 2003 to 2015 mainly responsible for its technology matters, strategic development and marketing functions.
Alex Goddard joined AOBiome in 2018 as VP of Research and Development. Alex brings a wealth of experience in strategy and execution. He has worked to progress therapeutics spanning pharmaceutical, device, and digital health approaches, with previous positions at Novartis, Tal Medical, and Sync Project. His areas of scientific expertise include neuron-immune interactions, neurological and psychiatric disease, and ammonia-oxidizing bacteria.
Dr. Goddard received bachelor’s degrees in Neuroscience and in Biochemistry from Oberlin College, his Ph.D. in Neurobiology from Harvard University, and did his postdoctoral work at Stanford University. He has authored numerous scientific publications. He is also a doting father, an avid musician, and a tolerable cook.
David Whitlock is the Inventor and co-founder of AOBiome. His initial discovery that Ammonia Oxidizing Bacteria could be reintroduced to the human microbiome formed the scientific basis for AOBiome’s efforts. Mr. Whitlock holds both an MS and a BS in Chemical Engineering from MIT and is the author or co-author of several key patents in the field.